Related Experiment Video

Updated: May 8, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells

Bin Jia1, Edwin Choy, Gregory Cote

  • 1Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Cancer Letters
|September 7, 2013
PubMed

Insights

Targeting cyclin-dependent kinase 11 (CDK11) inhibits liposarcoma growth and increases chemotherapy effectiveness. This study highlights CDK11 as a potential therapeutic target for liposarcoma, offering new treatment avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Liposarcoma is a prevalent soft tissue sarcoma with limited therapeutic options.
  • Identifying novel therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of cyclin-dependent kinase 11 (CDK11) in liposarcoma.
  • To evaluate CDK11 as a potential therapeutic target for liposarcoma treatment.

Main Methods:

  • CDK11 knockdown was achieved using synthetic siRNA and lentiviral shRNA.
  • Cell proliferation and apoptosis assays were performed.
  • The combined effect of CDK11 knockdown and doxorubicin treatment was assessed.

Main Results:

  • CDK11 knockdown significantly reduced liposarcoma cell proliferation.
  • CDK11 knockdown induced apoptosis in liposarcoma cells.
  • Combined CDK11 inhibition and doxorubicin enhanced cytotoxic effects and inhibited cell growth.

Conclusions:

  • CDK11 is essential for the growth and proliferation of liposarcoma cells.
  • CDK11 represents a promising therapeutic target for liposarcoma.
  • Targeting CDK11 may enhance the efficacy of existing chemotherapy regimens.
Keywords:
CDK11ImmunohistochemistryKinaseLiposarcomaTissue microarray

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.